Search Results - "Schaper, Carl"

Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy by DOWSETT, Mitch, SESTAK, Ivana, LOPEZ-KNOWLES, Elena, SIDHU, Kalvinder, DUNBIER, Anita K, COWENS, J. Wayne, FERREE, Sean, STORHOFF, James, SCHAPER, Carl, CUZICK, Jack

“…Risk of distant recurrence (DR) among women with estrogen receptor (ER) -positive early breast cancer is the major determinant of recommendations for or…”
Get full text

Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score by Sestak, Ivana, Cuzick, Jack, Dowsett, Mitch, Lopez-Knowles, Elena, Filipits, Martin, Dubsky, Peter, Cowens, John Wayne, Ferree, Sean, Schaper, Carl, Fesl, Christian, Gnant, Michael

“…We have previously shown that the PAM50-based risk of recurrence (ROR) score is significantly correlated with distant recurrence in both the translational…”
Get full text

Development and verification of the PAM50-based Prosigna breast cancer gene signature assay by Wallden, Brett, Storhoff, James, Nielsen, Torsten, Dowidar, Naeem, Schaper, Carl, Ferree, Sean, Liu, Shuzhen, Leung, Samuel, Geiss, Gary, Snider, Jacqueline, Vickery, Tammi, Davies, Sherri R, Mardis, Elaine R, Gnant, Michael, Sestak, Ivana, Ellis, Matthew J, Perou, Charles M, Bernard, Philip S, Parker, Joel S

“…The four intrinsic subtypes of breast cancer, defined by differential expression of 50 genes (PAM50), have been shown to be predictive of risk of recurrence…”
Get full text

Evaluation of Versant Hepatitis C Virus Genotype Assay (LiPA) 2.0 by Verbeeck, Jannick, Stanley, Mark J, Shieh, Jen, Celis, Linda, Huyck, Els, Wollants, Elke, Morimoto, Judy, Farrior, Alice, Sablon, Erwin, Jankowski-Hennig, Margaret, Schaper, Carl, Johnson, Pamela, Van Ranst, Marc, Van Brussel, Marianne

“…Hepatitis C virus (HCV) genotyping is a tool used to optimize antiviral treatment regimens. The newly developed Versant HCV genotype assay (LiPA) 2.0 uses…”
Get full text

Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens by Nielsen, Torsten, Wallden, Brett, Schaper, Carl, Ferree, Sean, Liu, Shuzhen, Gao, Dongxia, Barry, Garrett, Dowidar, Naeem, Maysuria, Malini, Storhoff, James

“…NanoString's Prosigna™ Breast Cancer Prognostic Gene Signature Assay is based on the PAM50 gene expression signature. The test outputs a risk of recurrence…”
Get full text

PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer by Lænkholm, Anne-Vibeke, Jensen, Maj-Britt, Eriksen, Jens Ole, Rasmussen, Birgitte Bruun, Knoop, Ann S, Buckingham, Wesley, Ferree, Sean, Schaper, Carl, Nielsen, Torsten O, Haffner, Taryn, Kibøl, Torben, Møller Talman, Maj-Lis, Bak Jylling, Anne Marie, Tabor, Tomasz Piotr, Ejlertsen, Bent

“…Purpose The PAM50-based Prosigna risk of recurrence (ROR) score has been validated in randomized clinical trials to predict 10-year distant recurrence (DR)…”
Get full text

The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer by FILIPITS, Martin, NIELSEN, Torsten O, MÜLLER-HOLZNER, Elisabeth, SINGER, Christian F, MLINERITSCH, Brigitte, DUBSKY, Peter, BAUERNHOFER, Thomas, HUBALEK, Michael, KNAUER, Michael, TRAPL, Harald, FESL, Christian, SCHAPER, Carl, RUDAS, Margaretha, FERREE, Sean, SHUZHEN LIU, COWENS, J. Wayne, GNANT, Michael, GREIL, Richard, STÖGER, Herbert, JAKESZ, Raimund, BAGO-HORVATH, Zsuzsanna, DIETZE, Otto, REGITNIG, Peter, GRUBER-ROSSIPAL, Christine

“…To assess the prognostic value of the PAM50 risk-of-recurrence (ROR) score on late distant recurrence (beyond 5 years after diagnosis and treatment) in a large…”
Get full text

Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay by Prat, Aleix, Galván, Patricia, Jimenez, Begoña, Buckingham, Wesley, Jeiranian, H Arthur, Schaper, Carl, Vidal, Maria, Álvarez, Martina, Díaz, Sherley, Ellis, Catherine, Nuciforo, Paolo, Ferree, Sean, Ribelles, Nuria, Adamo, Barbara, Ramón Y Cajal, Santiago, Peg, Vicente, Alba, Emilio

“…Most hormone receptor (HR)(+)/HER2(-) breast cancer patients respond unfavorably to neoadjuvant chemotherapy (NAC); however, genomic tests may identify those…”
Get full text

Validating critical analytical variables of a multiplexed gene expression assay measuring tumor inflammation designed to predict response to anti-PD1 therapy by Popa, Simina, Church, Sarah Elizabeth, Pekker, Irena, Dowidar, Naeem, Sullivan, Amy, Ngouenet, Celine, Schaper, Carl, Ren, Xing, Danaher, Patrick, Ferree, Sean, Wallden, Brett

“…Abstract only 203 Background: The development and analytical performance of the Tumor Inflammation Signature (TIS) assay has been described previously. The TIS…”
Get full text

Development of the molecular diagnostic (MDx) DLBCL Lymphoma Subtyping Test (LST) on the nCounter Analysis System by Wallden, Brett, Ferree, Sean, Ravi, Harini, Dowidar, Naeem, Hood, Tressa, Danaher, Patrick, Mashadi-Hossein, Afshin, Wright, George, Schaper, Carl, Storhoff, James Justin

“…Abstract only…”
Get full text

Prediction of late distant recurrence (DR) using the Prosigna (PAM50) test in a Danish Breast Cancer Cooperative Group (DBCG) cohort of postmenopausal women diagnosed with hormone receptor-positive (HR+) early breast cancer (EBC) allocated to 5yr of endocrine therapy (ET) by Lænkholm, Anne-Vibeke, Jensen, Maj-Britt, Eriksen, Jens Ole, Kibøll, Torben, Bruun Rasmussen, Birgitte, Knoop, Ann S., Ferree, Sean, Haffner, Taryn, Schaper, Carl, Ejlertsen, Bent

“…Abstract only…”
Get full text

Prediction of 10yr distant recurrence (DR) using the Prosigna (PAM50) assay in a Danish Breast Cancer Cooperative Group (DBCG) cohort of postmenopausal Danish women with hormone receptor-positive (HR+) early breast cancer (EBC) allocated to 5yr of endocrine therapy (ET) alone by Lænkholm, Anne-Vibeke, Jensen, Maj-Britt, Eriksen, Jens Ole, Kibøll, Torben, Bruun Rasmussen, Birgitte, Knoop, Ann S., Ferree, Sean, Haffner, Taryn, Schaper, Carl, Ejlertsen, Bent

“…Abstract only…”
Get full text

Validation of prediction of distant recurrence (DR) by Prosigna (PAM50) in subgroups of a Danish Breast Cancer Cooperative Group (DBCG) cohort of node-positive (N1), hormone receptor positive (HR+), postmenopausal early breast cancer (EBC) patients allocated 5yr of endocrine therapy (ET) by Ejlertsen, Bent, Jensen, Maj-Britt, Eriksen, Jens Ole, Kibøll, Torben, Bruun Rasmussen, Birgitte, Knoop, Ann S., Ferree, Sean, Haffner, Taryn, Schaper, Carl, Lænkholm, Anne-Vibeke

“…Abstract only…”
Get full text

A Commutable Cytomegalovirus Calibrator Is Required to Improve the Agreement of Viral Load Values between Laboratories by Caliendo, Angela M, Shahbazian, Mona D, Schaper, Carl, Ingersoll, Jessica, Abdul-Ali, Deborah, Boonyaratanakornkit, Jerry, Pang, Xiao-Li, Fox, Julie, Preiksaitis, Jutta, Schonbrunner, E. Ralf

“…Viral load testing for cytomegalovirus (CMV) is an important diagnostic tool for the management of transplant recipients and immunocompromised individuals;…”
Get full text

Comparison of PAM50 Risk of Recurrence Score With Onco type DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy by Dowsett, Mitch, Sestak, Ivana, Lopez-Knowles, Elena, Sidhu, Kalvinder, Dunbier, Anita K., Cowens, J. Wayne, Ferree, Sean, Storhoff, James, Schaper, Carl, Cuzick, Jack

“…Purpose Risk of distant recurrence (DR) among women with estrogen receptor (ER) –positive early breast cancer is the major determinant of recommendations for…”
Get full text

Blinded independent validation of the PAM50-based Chemo-Endocrine Sensitivity Predictor (CESP) in hormone receptor (HR)-positive/HER2-negative (HR+/HER2-) breast cancer following neoadjuvant chemotherapy (NAC) by Prat, Aleix, Jimenez Rodriguez, Begona, Sánchez Rovira, Pedro, Alvarez, Martina, Vicioso, Luis, de Luque, Vanessa, Fernandez-Sousa, Cristina, Parrado, M Rosario Chica, Santonja, Angela, Ramirez Tortosa, Cesar, Lavado Fernandez, Ana Isabel, Perez Ruiz, Elisabeth, Gonzalez-Hermoso, Carlos, Buckingham, Wesley, Dowidar, Naeem, Ferree, Sean, Jeiranian, Arthur, Schaper, Carl, Ribelles, Nuria, Alba, Emilio

“…Abstract only…”
Get full text

Prosigna (PAM50) to predict response to neoadjuvant chemotherapy (NAC) in HR+/HER2- early breast cancer (EBC) patients by Jimenez Rodriguez, Begona, Lavado Fernandez, Ana Isabel, Ribelles, Nuria, Sanchez-Rovira, Pedro, Vicioso, Luis, Alvarez, Martina, de Luque, Vanessa, Ramirez Tortosa, Cesar, Buckingham, Wesley, Schaper, Carl, Jeiranian, Arthur, Dowidar, Naeem, Ferree, Sean, Villar, Ester, Zarcos, Irene, Sanchez-Muñoz, Alfonso, Gonzalez-Hermoso, Carlos, Llacer Perez, Casilda, Prat, Aleix, Alba, Emilio

“…Abstract only…”
Get full text

Multicenter evaluation of the Bayer VERSANT™ HIV-1 RNA 3.0 assay: analytical and clinical performance by Gleaves, Curt A., Welle, John, Campbell, Mary, Elbeik, Tarek, Ng, Valerie, Taylor, Patricia E., Kuramoto, Ken, Aceituno, Sherri, Lewalski, Eva, Joppa, Barbara, Sawyer, Lynette, Schaper, Carl, McNairn, Denise, Quinn, Thomas

“…Background: The use of quantitative HIV-1 RNA assays is part of the standard of care for the management of HIV-1-infected individuals. Objective: The Bayer…”
Get full text

Statistical issues in the design of HIV vaccine trials by Schaper, C, Fleming, T R, Self, S G, Rida, W N

“…HIV vaccine trials present significant challenges related to trial endpoints, vaccine efficacy measurement, and the role of nonvaccine interventions. Infection…”
Get full text

Multicriteria optimization of nondifferentiable stochastic biosystems: Technology management of irrigated maize by Schaper, James Carl

“…A mathematical model of an irrigated maize enterprise, from preseason manure application to the transport of grain to market, is constructed and used to…”
Get full text